ClinicalTrials.gg
CompletedNCT00842244Updated Nov 27, 2013Results posted

Study Of Axitinib In Combination With Cisplatin And Capecitabine In Patients With Advanced Gastric Cancer

A Phase 1 interventional study of axitinib and capecitabine in Stomach Neoplasms and Advanced Gastric Cancer, sponsored by Pfizer. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-11-27.

Sponsored by Pfizer · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies in Stomach Neoplasms by Pfizer — 5 open to participants now, 7 under way, 1 of them phase 3. Stomach Neoplasms · Pfizer.

Enrollment
23rd of 25
22 · median 79
Started
2009
the only one that year
Phase 1
18 of 27
4 open now
Registered
7th of 27
by date

Among the 27 studies in Stomach Neoplasms by Pfizer, this one is the 23rd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2009, is one of 18 in phase 1, and was the 7th registered.

Stomach Neoplasms

3,403 studies on the registry are indexed under Stomach Neoplasms; 993 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

5 of the 27 studies in Stomach Neoplasms by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Stomach Neoplasms by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safe and tolerable dose of axitinib given together with cisplatin and capecitabine in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.

03

Conditions studied

  • Stomach Neoplasms
  • Advanced Gastric Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed diagnosis of stomach cancer
  • advanced stomach cancer of stage IV
  • adequate blood chemistry, blood counts and kidney function
  • willing to participate to study requirements and sign an document

Exclusion criteria

Exclusion Criteria:

  • prior chemotherapy for stomach cancer in its advanced stage
  • excessive toxicities related to prior therapies
  • pregnant or breastfeeding patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    A

    Drug: axitinib · Drug: capecitabine · Drug: cisplatin

Interventions

  • Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

  • Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m\^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.

  • Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m\^2 on day 1.

06

What researchers measure

Primary outcomes

  1. Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)

    DLT = Grade (GR) 2 proteinuria; GR3 nonhematological toxicity (NHT) (excluding alopecia and those that can be controlled with appropriate treatment) for greater than or equal to (\>=)7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile neutropenia (NP) or NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.

    Time frame: Baseline up to Day 21 of Cycle 1

Secondary outcomes

  1. Maximum Observed Plasma Concentration (Cmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

    Cmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Cmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-fluorouracil \[5-FU\], 5-deoxy-5-fluorouridine \[5-DFUR\] and 5-deoxy-5-fluorocytidine \[5-DFC\]) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on Cycle 1 (C1) Day -1 (D-1), C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1

  2. Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

    Tmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Tmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1

  3. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Capecitabine, Capecitabine's Metabolites and Cisplatin

    Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR, 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.

    Time frame: 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1

  4. Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] for Axitinib

    AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours. AUC (0-24) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Results for axitinib were normalized to axitinib 5 mg dose.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1

  5. Area Under the Curve From Time Zero Extrapolated to Infinite Time [AUC (0 - ∞)] for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

    AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. AUC (0 - ∞) for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1

  6. Plasma Decay Half-Life (t1/2) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

    Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Plasma decay half life for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1

  7. Apparent Oral Clearance (CL/F) for Axitinib, Capecitabine and Capecitabine's Metabolites

    Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. CL/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose on C1D1, C2D1

  8. Clearance (CL) for Cisplatin

    Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It is defined as the volume of blood from which drug can be completely removed per unit of time. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start on C1D1, C2D1

  9. Apparent Volume of Distribution (Vz/F) for Axitinib, Capecitabine and Capecitabine's Metabolites

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Vz/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.

    Time frame: 0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose on C1D1, C2D1

  10. Volume of Distribution (Vz) for Cisplatin

    Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.

    Time frame: 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start on C1D1, C2D1

  11. Drug Metabolizing Enzyme Genotyping

    Genetic variants of uridine diphosphate (UDP)- glucuronosyl transferase 1A1 (UGT1A1) gene which were assessed for genotyping included UGT1A1\*60, UGT1A1-3156, UGT1A1 Promoter thymine adenine (TA) repeat (UGT1A1\*28, UGT1A1\*36, UGT1A1\*37), UGT1A1\*6 and UGT1A1\*27.

    Time frame: Day 1 of Cycle 1

  12. Percentage of Participants With Objective Response (OR)

    Number of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent (%) decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.

    Time frame: Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784

  13. Duration of Response (DR)

    Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR = disappearance of all target lesions. PR = at least 30% decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.

    Time frame: Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784

  14. Progression-Free Survival (PFS)

    Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). PD was a\>=20% increase in sum of the longest dimensions of target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

    Time frame: Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784

Other outcomes

  1. Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine

    MTD = highest dose at which no more than 30 percent (%) of 12 participants experience DLT during Cycle 1. DLT = GR2 proteinuria; GR3 NHT (excluding alopecia and those that can be controlled with appropriate treatment)for \>=7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile NP/NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment-related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.

    Time frame: Baseline up to Day 21 of Cycle 1

07

Results

Posted Mar 26, 2012
Limitations and caveats
AUC (0-24) was evaluated and reported for axitinib instead of AUClast as AUC0-24 was a more appropriate measure of steady-state exposure for this drug.

Participant flow

Participant flow — Overall Study
MilestoneAxitinib + Capecitabine + Cisplatin
Started22
Completed1
Not completed21
Withdrew: Death3
Withdrew: Withdrawal by subject1
Withdrew: Other17

Outcome measures

PrimaryNumber of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)

DLT = Grade (GR) 2 proteinuria; GR3 nonhematological toxicity (NHT) (excluding alopecia and those that can be controlled with appropriate treatment) for greater than or equal to (\>=)7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile neutropenia (NP) or NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.

Time frame:
Baseline up to Day 21 of Cycle 1
Reported as:
Number · participants
Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)
participantsAxitinib + Capecitabine + Cisplatin (MTD Determination)
Number of Participants With Cycle 1 Dose-limiting Toxicities (DLTs)3
Other pre-specifiedMaximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine

MTD = highest dose at which no more than 30 percent (%) of 12 participants experience DLT during Cycle 1. DLT = GR2 proteinuria; GR3 NHT (excluding alopecia and those that can be controlled with appropriate treatment)for \>=7 days, GR3 thrombocytopenia with active bleeding; GR \>=3 febrile NP/NP infection; GR 3 or 4 nausea, vomiting or diarrhea despite anti-emetics, anti-diarrheals; GR4 NHT, thrombocytopenia, NP for \>=7 days; \>= 1/2 teaspoon per day hemoptysis; any treatment-related toxicity with \>3 consecutive days of capecitabine or 5 consecutive days of axitinib missed doses per cycle; delayed toxicity recovery \>14 days.

Time frame:
Baseline up to Day 21 of Cycle 1
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine
mgAxitinib + Capecitabine + Cisplatin (MTD Determination)
Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Cisplatin and Capecitabine5
SecondaryMaximum Observed Plasma Concentration (Cmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

Cmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Cmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-fluorouracil \[5-FU\], 5-deoxy-5-fluorouridine \[5-DFUR\] and 5-deoxy-5-fluorocytidine \[5-DFC\]) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on Cycle 1 (C1) Day -1 (D-1), C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Reported as:
Geometric mean · nanogram/milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
nanogram/milliliter (ng/mL)Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone (n = 10)16.11 (9.94 to 26.10)
Axitinib in combination with chemotherapy (n = 10)24.33 (15.01 to 39.43)
Capecitabine alone (n = 8)5255.62 (3155.36 to 8753.85)
Capecitabine in presence of axitinib (n = 8)2274.80 (1365.74 to 3788.95)
5-FU alone (n = 8)220.49 (132.31 to 367.44)
5-FU in presence of axitinib (n = 8)90.97 (54.59 to 151.59)
5-DFUR alone (n = 8)5791.81 (3871.80 to 8663.95)
5-DFUR in presence of axitinib (n = 8)3017.27 (2017.03 to 4513.52)
5-DFC alone (n = 8)5891.29 (4416.64 to 7858.31)
5-DFC in presence of axitinib (n = 8)3227.57 (2419.68 to 4305.21)
Cisplatin alone (n = 8)1665.27 (1407.48 to 1970.26)
Cisplatin in presence of axitinib (n = 8)1865.07 (1576.36 to 2206.66)
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

Tmax for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Tmax for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Reported as:
Median · hrs
Time to Reach Maximum Observed Plasma Concentration (Tmax) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
hrsAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone (n = 10)3.98 (0.00 to 7.97)
Axitinib in combination with chemotherapy (n = 10)4.00 (1.00 to 6.00)
Capecitabine alone (n = 8)2.45 (0.50 to 4.00)
Capecitabine in presence of axitinib (n = 8)3.12 (0.50 to 4.02)
5-FU alone (n = 8)2.50 (0.50 to 4.07)
5-FU in presence of axitinib (n = 8)2.62 (0.50 to 4.02)
5-DFUR alone (n = 8)2.50 (0.50 to 4.07)
5-DFUR in presence of axitinib (n = 8)2.62 (0.97 to 4.02)
5-DFC alone (n = 8)2.50 (0.50 to 4.07)
5-DFC in presence of axitinib (n = 8)3.09 (0.50 to 4.02)
Cisplatin alone (n = 8)2.00 (1.00 to 2.20)
Cisplatin in presence of axitinib (n = 8)1.02 (0.97 to 2.33)
SecondaryArea Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Capecitabine, Capecitabine's Metabolites and Cisplatin

Area under the plasma concentration time-curve from zero to the last measurable concentration (AUClast). AUClast for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR, 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.

Time frame:
0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Reported as:
Geometric mean · nanogram*hour/milliliter (ng*hr/mL)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Capecitabine, Capecitabine's Metabolites and Cisplatin
nanogram*hour/milliliter (ng*hr/mL)Axitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Capecitabine alone7109.59 (4525.07 to 11170.27)
Capecitabine in presence of axitinib4194.97 (2669.99 to 6590.95)
5-FU alone332.37 (238.03 to 464.12)
5-FU in presence of axitinib176.81 (126.62 to 246.89)
5-DFUR alone9996.55 (8183.62 to 12211.10)
5-DFUR in presence of axitinib6683.33 (5471.27 to 8163.90)
5-DFC alone10820.14 (8838.29 to 13246.37)
5-DFC in presence of axitinib7983.14 (6520.93 to 9773.23)
Cisplatin alone3814.93 (3463.52 to 4202.00)
Cisplatin in presence of axitinib3951.57 (3587.57 to 4352.50)
SecondaryArea Under the Curve From Time Zero to 24 Hours [AUC (0-24)] for Axitinib

AUC (0-24) = Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours. AUC (0-24) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Results for axitinib were normalized to axitinib 5 mg dose.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero to 24 Hours [AUC (0-24)] for Axitinib
ng*hr/mLAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone206.20 (109.20 to 389.36)
Axitinib in combination with chemotherapy265.89 (140.81 to 502.08)
SecondaryArea Under the Curve From Time Zero Extrapolated to Infinite Time [AUC (0 - ∞)] for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) extrapolated to infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). AUC (0 - ∞) for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. AUC (0 - ∞) for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1. Results for axitinib were normalized to axitinib 5 mg dose, results for capecitabine and its metabolites (5-FU, 5-DFUR and 5-DFC) were normalized to Cycle 1 Day 1 capecitabine dose and results for cisplatin were normalized to Cycle 1 Day 1 cisplatin dose.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Reported as:
Geometric mean · ng*hr/mL
Area Under the Curve From Time Zero Extrapolated to Infinite Time [AUC (0 - ∞)] for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
ng*hr/mLAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone (n = 9)147.04 (70.79 to 305.42)
Axitinib in combination with chemotherapy (n = 9)156.00 (75.10 to 324.02)
Capecitabine alone (n = 6)7140.62 (4197.86 to 12146.29)
Capecitabine in presence of axitinib (n = 6)4213.72 (2477.18 to 7167.60)
5-FU alone (n = 3)337.85 (198.44 to 575.20)
5-FU in presence of axitinib (n = 3)261.95 (153.86 to 445.98)
5-DFUR alone (n = 4)9568.70 (6772.04 to 13520.28)
5-DFUR in presence of axitinib (n = 4)6966.07 (4930.09 to 9842.84)
5-DFC alone (n = 5)11587.97 (7974.00 to 16839.87)
5-DFC in presence of axitinib (n = 5)7787.39 (5358.71 to 11316.78)
Cisplatin alone (n = 7)3979.07 (3577.60 to 4425.59)
Cisplatin in presence of axitinib (n = 7)3990.34 (3587.74 to 4438.12)
SecondaryPlasma Decay Half-Life (t1/2) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. Plasma decay half life for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Plasma decay half life for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate), capecitabine and capecitabine's metabolites (5-FU, 5-DFUR and 5-DFC) in presence of steady-state axitinib were evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin/capecitabine alone) on Cycle 2 Day 1.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose C1D1, C2D1; 0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start C1D1, C2D1
Reported as:
Mean · hrs
Plasma Decay Half-Life (t1/2) for Axitinib, Capecitabine, Capecitabine's Metabolites and Cisplatin
hrsAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone (n = 9)5.76 ± 3.665
Axitinib in combination with chemotherapy (n = 9)3.50 ± 1.869
Capecitabine alone (n = 6)0.71 ± 0.441
Capecitabine in presence of axitinib (n = 6)0.89 ± 0.520
5-FU alone (n = 3)1.11 ± 0.455
5-FU in presence of axitinib (n = 3)1.05 ± 0.506
5-DFUR alone (n = 4)0.96 ± 0.400
5-DFUR in presence of axitinib (n = 4)0.77 ± 0.125
5-DFC alone (n = 5)0.98 ± 0.499
5-DFC in presence of axitinib (n = 5)0.78 ± 0.147
Cisplatin alone (n = 7)1.25 ± 0.095
Cisplatin in presence of axitinib (n = 7)1.61 ± 0.772
SecondaryApparent Oral Clearance (CL/F) for Axitinib, Capecitabine and Capecitabine's Metabolites

Clearance (CL) of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed (F). Clearance is defined as the volume of blood from which drug can be completely removed per unit of time. CL/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. CL/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose on C1D1, C2D1
Reported as:
Geometric mean · Liter/hr
Apparent Oral Clearance (CL/F) for Axitinib, Capecitabine and Capecitabine's Metabolites
Liter/hrAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone (n = 9)48.55 (25.71 to 91.70)
Axitinib in combination with chemotherapy (n = 9)37.69 (19.96 to 71.19)
Capecitabine alone (n = 6)217.60 (118.45 to 399.74)
Capecitabine in presence of axitinib (n = 6)368.47 (200.58 to 676.89)
SecondaryClearance (CL) for Cisplatin

Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. It is defined as the volume of blood from which drug can be completely removed per unit of time. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start on C1D1, C2D1
Reported as:
Geometric mean · Liter/hr
Clearance (CL) for Cisplatin
Liter/hrAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Cisplatin alone30.94 (26.03 to 36.77)
Cisplatin in presence of axitinib32.50 (27.35 to 38.63)
SecondaryApparent Volume of Distribution (Vz/F) for Axitinib, Capecitabine and Capecitabine's Metabolites

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Vz/F is influenced by the fraction absorbed. Vz/F for axitinib in absence of chemotherapy (axitinib alone) was evaluated on Cycle 1 Day -1 and in combination with chemotherapy on Cycle 1 Day 1. Vz/F for capecitabine in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (capecitabine alone) on Cycle 2 Day 1.

Time frame:
0 (pre-dose), 1, 2, 3, 4, 6, 8 hrs post-axitinib dose on C1D-1, C1D1; 0 (pre-dose), 0.25, 0.5, 1, 2, 3, 4, 6, 8 hrs post-capecitabine dose on C1D1, C2D1
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution (Vz/F) for Axitinib, Capecitabine and Capecitabine's Metabolites
LiterAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Axitinib alone (n = 9)344.87 (202.24 to 588.09)
Axitinib in combination with chemotherapy (n = 9)171.83 (100.77 to 293.01)
Capecitabine alone (n = 6)190.94 (89.08 to 409.30)
Capecitabine in presence of axitinib (n = 6)425.00 (198.27 to 911.02)
SecondaryVolume of Distribution (Vz) for Cisplatin

Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Clearance for cisplatin (assessed by estimating total platinum in plasma ultrafiltrate) in presence of steady-state axitinib was evaluated on Cycle 1 Day 1 and in absence of axitinib (cisplatin alone) on Cycle 2 Day 1.

Time frame:
0 (pre-dose), 0.5, 1, 2, 3, 4, 6, 8 hrs post-cisplatin infusion start on C1D1, C2D1
Reported as:
Geometric mean · Liter
Volume of Distribution (Vz) for Cisplatin
LiterAxitinib + Capecitabine + Cisplatin (PK Expansion Cohort)
Cisplatin alone55.35 (41.12 to 74.51)
Cisplatin in presence of axitinib70.32 (52.24 to 94.66)
SecondaryDrug Metabolizing Enzyme Genotyping

Genetic variants of uridine diphosphate (UDP)- glucuronosyl transferase 1A1 (UGT1A1) gene which were assessed for genotyping included UGT1A1\*60, UGT1A1-3156, UGT1A1 Promoter thymine adenine (TA) repeat (UGT1A1\*28, UGT1A1\*36, UGT1A1\*37), UGT1A1\*6 and UGT1A1\*27.

Time frame:
Day 1 of Cycle 1

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Objective Response (OR)

Number of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are those with disappearance of all target lesions. PR are those with at least 30 percent (%) decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.

Time frame:
Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (OR)
percentage of participantsAxitinib + Capecitabine + Cisplatin
Percentage of Participants With Objective Response (OR)36.36 (17.2 to 59.34)
SecondaryDuration of Response (DR)

Time in months from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4. DR was calculated for the subgroup of participants with a confirmed objective tumor response. CR = disappearance of all target lesions. PR = at least 30% decrease in sum of the longest dimensions of target lesions taking the baseline sum of the longest dimensions as a reference.

Time frame:
Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784
Reported as:
Median · months
Duration of Response (DR)
monthsAxitinib + Capecitabine + Cisplatin
Duration of Response (DR)9.07 (6.44 to 20.20)
SecondaryProgression-Free Survival (PFS)

Time in months from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 30.4. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death"). PD was a\>=20% increase in sum of the longest dimensions of target lesions taking as a reference the smallest sum of the longest dimensions recorded since the treatment started, or the appearance of 1 or more new lesions.

Time frame:
Baseline up to disease progression or withdrawal, assessed on Day 21 of every other cycle starting from Cycle 2 up to Day 784
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsAxitinib + Capecitabine + Cisplatin
Progression-Free Survival (PFS)3.75 (2.92 to 9.40)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib + Capecitabine + Cisplatin—12/22 (54.5%)22/22 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventAxitinib + Capecitabine + Cisplatin
Disease progressionGeneral disorders2/22
BradycardiaCardiac disorders1/22
EnterocolitisGastrointestinal disorders1/22
Gastrointestinal haemorrhageGastrointestinal disorders1/22
Gastrointestinal perforationGastrointestinal disorders1/22
NauseaGastrointestinal disorders1/22
VomitingGastrointestinal disorders1/22
Decreased appetiteMetabolism and nutrition disorders1/22
HeadacheNervous system disorders1/22
HypoaesthesiaNervous system disorders1/22
Most frequent other events
Showing 10 of 55
Most frequent other events
EventAxitinib + Capecitabine + Cisplatin
Decreased appetiteMetabolism and nutrition disorders20/22
NauseaGastrointestinal disorders17/22
FatigueGeneral disorders17/22
StomatitisGastrointestinal disorders16/22
HypertensionVascular disorders16/22
NeutropeniaBlood and lymphatic system disorders14/22
ThrombocytopeniaBlood and lymphatic system disorders12/22
DiarrhoeaGastrointestinal disorders12/22
DysphoniaRespiratory, thoracic and mediastinal disorders12/22
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders12/22

Baseline characteristics

Age Continuous
Age Continuous(years)Axitinib + Capecitabine + Cisplatin
Mean59.3 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib + Capecitabine + Cisplatin
Female6
Male16
08

Study locations

5 sites
  • Pfizer Investigational Site
    Kashiwa, Chiba, Japan
  • Pfizer Investigational Site
    Yufu-city, Oita, Japan
  • Pfizer Investigational Site
    Goyang-si, Gyeonggi-do 410-769, Korea, Republic of
  • Pfizer Investigational Site
    Seongnam-si, Gyeonggi-do 463-707, Korea, Republic of
  • Pfizer Investigational Site
    Seoul, 110-744, Korea, Republic of
09

References and documents

Publications

  • Oh DY, Doi T, Shirao K, Lee KW, Park SR, Chen Y, Yang L, Valota O, Bang YJ. Phase I Study of Axitinib in Combination with Cisplatin and Capecitabine in Patients with Previously Untreated Advanced Gastric Cancer. Cancer Res Treat. 2015 Oct;47(4):687-96. doi: 10.4143/crt.2014.225. Epub 2015 Feb 12. PubMed 25687867 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Dec 2009 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 2 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2009
First posted
Feb 12, 2009
Start
Apr 2009
Primary completionActual
Dec 2009
CompletionActual
Oct 2012
Results first posted
Mar 26, 2012
Last update
Nov 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00842244
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 12, 2009
Start date
Apr 2009
Primary completion
Dec 2009
Completion
Oct 2012
Results posted
Mar 26, 2012
Last update
Nov 27, 2013

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion